Exscientia Bags Roche As AI Partner And $26m Series B To Fund Own Pipeline

Exscientia's top executives tell Scrip why Roche opted for its AI insights - and how the UK group will use a $26m series B financing to build its proprietary pipeline.

Robot
AI group Exscientia raises $26m to expand pipeline, adds Roche to partner list • Source: Shutterstock

Exscientia Ltd., the UK-based company that automates drug design with its AI-based platform, has added cancer specialist Roche to its growing list of pharma collaborators while also raising $26m in a Series B financing that will be used to aggressively expand its own pipeline in coming years.

Founded in 2012, Exscientia has been steadily expanding on the back of growing acceptance and use of artificial intelligence in drug innovation

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from AI

More from Digital Technologies